Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Yipinhong Pharmaceutical Co Ltd
Tax Provision
Yipinhong Pharmaceutical Co Ltd
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
|
Tax Provision
¥95.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Tax Provision
-¥995.1m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Tax Provision
-¥1.1B
|
CAGR 3-Years
-130%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-11%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Tax Provision
-¥853.3m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-6%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Tax Provision
-¥1B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-28%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Tax Provision
-¥270.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-126%
|
CAGR 10-Years
N/A
|
|
Yipinhong Pharmaceutical Co Ltd
Glance View
Yipinhong Pharmaceutical Co Ltd has carved its niche in the pharmaceutical landscape of China, with its roots embedded deeply in the nation's flourishing healthcare sector. Known for its dedication to combining traditional Chinese medicinal practices with modern scientific research, the company stands out in an increasingly competitive market. Yipinhong's operations are centered around developing, manufacturing, and distributing a broad spectrum of medicinal products that adhere to the highest quality standards. By focusing on therapeutic areas such as respiratory, cardiovascular, and gastrointestinal health, they strategically align with the growing demand for reliable medicinal solutions. What makes Yipinhong truly distinctive is its investment in research and development that drives innovation. This focus not only ensures a continuous pipeline of new products but positions them as a leader in the integration of traditional remedies with cutting-edge pharmaceutical science. The company thrives on a business model that maximizes its robust distribution network, encompassing both domestic and international markets. Yipinhong capitalizes on its vast network of sales agents and partnerships with hospitals, clinics, and pharmacies to ensure its products reach consumers efficiently. This network amplifies their revenue streams by tapping into various segments within the pharmaceutical supply chain. Moreover, Yipinhong's strategic collaborations for research and development and their participation in healthcare industry events bolster their market presence and brand recognition. By maintaining a harmonious balance between traditional approaches and modern demands, Yipinhong not only captures a unique market position but also sets a benchmark in pharmaceutical excellence and innovation.
See Also
What is Yipinhong Pharmaceutical Co Ltd's Tax Provision?
Tax Provision
95.9m
CNY
Based on the financial report for Sep 30, 2025, Yipinhong Pharmaceutical Co Ltd's Tax Provision amounts to 95.9m CNY.